Who is sponsoring NCT05565352?

NCT05565352 is sponsored by Medical University of Gdansk.

What drugs are being tested in NCT05565352?

Interventions in NCT05565352: Ketamine Hydrochloride.

What condition does NCT05565352 study?

NCT05565352 studies Major Depressive Disorder, Post Traumatic Stress Disorder, Obsessive-Compulsive Disorder, Somatoform Disorders, Anxiety Disorders, Dissociative Disorder.

Is NCT05565352 still recruiting?

NCT05565352 is currently enrolling by invitation. Last updated 2 April 2025.

Last reviewed 2025-04-02 · How we verify

NCT05565352: KetGD

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ketamine Safety and Tolerability in Psychiatric Inpatient Care (KetGD)

ENROLLING BY INVITATION Last updated 2 April 2025

What this trial tests

trial testing Ketamine Hydrochloride in Major Depressive Disorder in 140 participants. Enrolling by invitation.

Timeline

1 September 2022

Primary endpoint
31 December 2029

31 December 2029

Quick facts

Lead sponsor	Medical University of Gdansk
Status	ENROLLING BY INVITATION
Study type	OBSERVATIONAL
Enrollment	140
Start date	1 September 2022
Primary completion	31 December 2029
Estimated completion	31 December 2029
Sites	1 location across Poland

Drugs / interventions tested

Ketamine Hydrochloride — full drug profile →

Conditions studied

Major Depressive Disorder — all drugs for Major Depressive Disorder →
Post Traumatic Stress Disorder — all drugs for Post Traumatic Stress Disorder →
Obsessive-Compulsive Disorder — all drugs for Obsessive-Compulsive Disorder →
Somatoform Disorders — all drugs for Somatoform Disorders →

Sponsor

Medical University of Gdansk

Who can join

Adults 18 to 90, any sex, with Major Depressive Disorder or Post Traumatic Stress Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This observational registry aims to collect real-world data on ketamine use in psychiatric inpatients within a regional tertiary-reference center. The study evaluates the safety and tolerability of ketamine administration in individuals with treatment-resistant mental disorders, characterized by diverse comorbidities, heterogeneous disease courses, and variations in treatment responses based on illness stage and severity with a subset of patients with remitted-recurrent and treatment-resistant or chronic presentations. The registry is designed to systematically document adverse events, side effects, and patient-reported outcomes, providing a comprehensive assessment of both the short- and long-term effects of ketamine in psychopharmacology. By generating real-world evidence, this study shall contribute to a more nuanced understanding of ketamine's risk-benefit profile in clinical practice, particularly in subpopulations that are underrepresented in clinical trials. The findings prioritize the support for the refinement of treatment protocols and enhance patient safety in psychiatric care.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Ketamine for bipolar depression: an updated systematic review.
Fancy F, Haikazian S, Johnson DE, Chen-Li DCJ, et al · · 2023 · cited 15× · PMID 37771417 · DOI 10.1177/20451253231202723
Hereditary Patterns and Genetic Associations in Obsessive-Compulsive Disorder (OCD): Neuropsychiatric Insights, Genetic Influences, and Treatment Perspectives.
Dhiman A, Mehan S, Khan Z, Tiwari A, et al · · 2025 · cited 4× · PMID 39219434 · DOI 10.2174/0115665232316708240828063527
Residual Depressive Symptoms in Treatment-Resistant Bipolar Depression Following Short-Term Ketamine Administration.
Pastuszak M, Cubała WJ, Kwaśny A. · · 2024 · cited 3× · PMID 39269606 · DOI 10.1007/s40801-024-00453-y
Nonresponse to Ketamine in Treatment-Resistant Bipolar Depression.
Kachlik Z, Cubała WJ, Walaszek M, Pastuszak M, et al · · 2025 · cited 2× · PMID 40879542 · DOI 10.1002/npr2.70038
Clinical correlates of anhedonia non-response to ketamine in treatment-resistant depression.
Walaszek M, Cubała WJ, Kachlik Z, Pastuszak M, et al · · 2026 · PMID 41956221 · DOI 10.1016/j.jad.2026.121762
Anhedonia nonresponse to short-term ketamine administration for treatment-resistant bipolar depression.
Kachlik Z, Cubała WJ, Walaszek M, Pastuszak M, et al · · 2026 · PMID 41631109 · DOI 10.1177/20451253251412629
Ketamine dosing formula in treatment-resistant bipolar depression.
Kwaśny A, Jerzy Cubała W, Wilkowska A. · · 2025 · PMID 41262415 · DOI 10.1177/20451253251392817
Non-response to short-term ketamine use for treatment-resistant depression.
Walaszek M, Cubała WJ, Kachlik Z, Pastuszak M, et al · · 2025 · PMID 40305000 · DOI 10.1007/s43440-025-00730-9

Verify or expand the search:

Other trials of Ketamine Hydrochloride

Trials testing the same drug.

NCT05603104 — Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First- · Phase 3 · recruiting
NCT06090422 — Ketamine for Combined Depression and Alcohol Use Disorder · Phase 1, PHASE2 · not yet recruiting
NCT06496750 — Ketamine for Methamphetamine Use Disorder · Phase 2 · recruiting
NCT05973851 — The Effect of a Six Week Intensified Pharmacological Treatment for Major Depressive Disorder Compared to Treatment as Us · Phase 3 · recruiting
NCT06366334 — Study of IV Ketamine for Emergency Department Treatment of Adolescent Suicidal Ideation · NA · recruiting

Other recruiting trials for Major Depressive Disorder

Currently open trials in the same condition.

NCT07219394 — Peer-Delivered Behavioral Activation in a CCBHC · NA · recruiting
NCT06705478 — Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disor · Phase 2 · recruiting
NCT06749392 — An Individual-specific Synchrony Signature · NA · recruiting
NCT07316803 — Group Intervention for Romantic Relationships in Young Adults With Severe Mental Illness · NA · recruiting
NCT07242105 — Optimizing Brain Excitability in Depression · NA · recruiting

Other Medical University of Gdansk trials

Trials by the same sponsor.

NCT07521280 — State-Based Rehabilitation for Youth Athletes With Osgood-Schlatter or Sever-Related Apophyseal Pain · NA · not yet recruiting
NCT07446517 — Low-Level Laser Therapy for Osgood-Schlatter or Sever Pain in Youth Athletes · NA · recruiting
NCT07449585 — Pericapsular Nerve Group Block Versus Intrathecal Morphine for Analgesia After Total Hip Arthroplasty · NA · not yet recruiting
NCT07397208 — Assessment of the Repeatability of Sublingual Microcirculation Function Measurements in Healthy Volunteers and Criticall · not yet recruiting
NCT07345403 — GENECARD - the Use of Genetic, Epigenetic, Metabolomic, Proteomic and Microbiotic Markers, Image and Voice Biomarker Ana · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05565352 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Medical University of Gdansk
Last refreshed: 2 April 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05565352.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing